PT  - JOURNAL ARTICLE
AU  - van der Ploeg, Kattria
AU  - Kirosingh, Adam S.
AU  - Mori, Diego A. M.
AU  - Chakraborty, Saborni
AU  - Hu, Zicheng
AU  - Seivers, Benjamin L.
AU  - Jacobson, Karen B.
AU  - Bonilla, Hector
AU  - Parsonnet, Julie
AU  - Andrews, Jason R.
AU  - Press, Kathleen D.
AU  - Ty, Maureen C.
AU  - Ruiz-Betancourt, Daniel R.
AU  - de la Parte, Lauren
AU  - Tan, Gene S.
AU  - Blish, Catherine A.
AU  - Takahashi, Saki
AU  - Rodriguez-Barraquer, Isabel
AU  - Greenhouse, Bryan
AU  - Singh, Upinder
AU  - Wang, Taia T.
AU  - Jagannathan, Prasanna
TI  - TNFα-producing CD4<sup>+</sup> T cells dominate the SARS-CoV-2-specific T cell response in COVID-19 outpatients and are associated with durable antibodies
AID  - 10.1101/2022.01.25.22269670
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.25.22269670
4099  - http://medrxiv.org/content/early/2022/01/26/2022.01.25.22269670.short
4100  - http://medrxiv.org/content/early/2022/01/26/2022.01.25.22269670.full
AB  - SARS-CoV-2-specific CD4+ T cells are likely important in immunity against COVID-19, but our understanding of CD4+ longitudinal dynamics following infection and specific features that correlate with the maintenance of neutralizing antibodies remains limited. We characterized SARS-CoV-2-specific CD4+ T cells in a longitudinal cohort of 109 COVID-19 outpatients. The quality of the SARS-CoV-2-specific CD4+ response shifted from cells producing IFNγ to TNFα+ from five days to four months post-enrollment, with IFNγ-IL21-TNFα+ CD4+ T cells the predominant population detected at later timepoints. Greater percentages of IFNγ-IL21-TNFα+ CD4+ T cells on day 28 correlated with SARS-CoV-2 neutralizing antibodies measured seven months post-infection (ρ=0.4, P=0.01). mRNA vaccination following SARS-CoV-2 infection boosted both IFNγ and TNFα producing, spike protein-specific CD4+ T cells. These data suggest that SARS-CoV-2-specific, TNFα-producing CD4+ T cells may play an important role in antibody maintenance following COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04331899; IND 419217Funding StatementThis study was funded by NIH/NIAID (U01 AI150741-01S1, UL1 TR001085), the Stanfords Innovative Medicines Accelerator (Chem-H IMA), and a Fastgrant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was approved by Institutional Review Board of Stanford University (protocol 57230)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE178967